Catalogue Number: AB02248-202.1-BT-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | CD274; Programmed death ligand 1; PDL-1; PDL1 |
| Shipping Condition: | Blue Ice |
| Unit(s): | 1 mg |
| Host name: | Dog |
| Clone: | JC071 |
| Isotype: | IgG4 |
| Immunogen: | The original antibody was generated by immunizing BALB/c mice with recombinant canine PD-L1 using an exponentially increasing dosing strategy with MPLA as adjuvant. |
| Application: | ELISA, FC, WB, Blk |
CD274
Purified
Recombinant Monoclonal
484186
E2RKZ5
Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.
This antibody is recommended for detection of canine PD-L1. This antibody successfully detected canine PD-L1 in a western blot assay. JC071 was used to determine the increased PD-1 expression on canine PBMCs stimulated with peptidoglycan or lipopolysaccharide using flow cytometry. JC071 was also able to detect recombinant PD-L1 expressed on DH82 cell line both with and without in vitro activation using IFN-γ in flow cytometry. It also recognized recombinant canine PD-L1 expressed on CHO cells in flow cytometry. The ability of the antibody to block interactions between PD-1 and PD-L1 was checked using ELISA. It is known that blockade of PD-L1 and PD-1 interactions causes increase in Ifn-γ level. JC071 successfully blocked PD-L1 and amplified IFN-γ production in culture by approximately 6-fold. Thus, JC071 alleviated T-cell suppression and led to enhanced functional activity of T cells in culture and have potential application as an immunotherapy reagent for cancer treatment (PMID: 32614928).
This chimeric dog antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.